Jain, Ankit P <br/><br/>
MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.  [electronic resource] 

 -  Scientific reports  12 2019 
 - 18793 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-019-55208-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Cell Line, Tumor<br/>Datasets as Topic<br/>Drug Delivery Systems<br/>Drug Resistance, Neoplasm--genetics<br/>Epithelial-Mesenchymal Transition<br/>Erlotinib Hydrochloride--therapeutic use<br/>Genomics<br/>Humans<br/>MAP Kinase Kinase 1--antagonists & inhibitors<br/>Metabolic Networks and Pathways<br/>Phenotype<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proteomics<br/>Squamous Cell Carcinoma of Head and Neck--drug therapy<br/>Whole Genome Sequencing